Dr. Higano on the Effectiveness of PARP Inhibitors for Prostate Cancer

Celestia Higano, MD, professor of medicine and urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses the effectiveness of PARP inhibitors for patients with metastatic prostate cancer.

Approximately one-quarter of patients with metastatic prostate cancer have DNA-damaged alterations, states Higano. PARP inhibitors are a different treatment paradigm for prostate cancer that have shown to be effective in this patient population.